News › Clinical Practice, Industry News, Patient Care

CoolSculpting is Now FDA Approved to Improve Lax Tissue in Double Chin

December 28, 2017

The FDA has approved CoolSculpting treatment for the improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.  Allergan’s CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.
“In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini applicator for the CoolSculpting system to treat the submental area,” said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass. “It is great to see the company invest to validate this and secure the FDA clearance.”
An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.
Read more at the Aesthetic Channel >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations
    • Galderma to Acquire ZO Skin Health for $1.5 Billion
    • AscendPoint Agency Acquires Medical Marketing Whiz
    • PracticeQ Becomes Platinum Vendor Affiliate with the American Med Spa Association
Advertisement